Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Insulet

Tandem Diabetes Care

The worst performer among these stocks has soared more than 70% over the last 12 months.

Want to Get Rich Investing in Healthcare? Check Out These Diabetes Stocks

DexCom (DXCM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Increased Earnings Estimates Seen for DexCom (DXCM): Can It Move Higher?

DexCom (DXCM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why DexCom (DXCM) Stock Might be a Great Pick

Abbott Labs

Insulet's wearable insulin pumps will be integrated with blood glucose monitors from both companies.

Insulet Announces Agreements With Abbott and DexCom

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

As of late, it has definitely been a great time to be an investor in DexCom.

Will DexCom Continue to Surge Higher?

Shares have soared more than 400% in just two years.

Is DexCom's Stock a Buy?

Investors loved the medical device maker's great Q4 results.

Why DexCom Shares Are Flying Higher Today

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

The medical-device maker delivered good news across the board in the fourth quarter.

3 Reasons Why DexCom's Q4 Update Delighted Investors

DexCom, Inc. (DXCM) CEO Kevin Sayer on Q4 2019 Results - Earnings Call Transcript

Shares of the medical device manufacturer gained ground on the news.

DexCom Reports Q4 Earnings, Beats EPS and Revenue Targets

DexCom (DXCM) delivered earnings and revenue surprises of 53.33% and 1.27%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Q4 Earnings and Revenues Top Estimates

DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for DexCom (DXCM)

Duke Energy

Republic Services

TC Energy

Waste Management

Although corporate earnings growth was negative year over year in the first three quarters of last year, fourth-quarter results have been faring better than initially anticipated.

5 Must-Buy Corporate Giants Set to Beat on Earnings Tomorrow

DexCom's stock is now at all-time highs. Can this growth stock keep churning higher?

Why DexCom Stock Gained 10% in January

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

Amazon

Bank of America

Citigroup

Diamond Eagle Acquisition Corp - Unit (1 Ordinary share Cls A & 1/3 Wrt)

JPMorgan Chase & Co

Morgan Stanley

Teladoc

The Corrective Phase Has Begun, What To Do?

Both medical device stocks have characteristics investors should consider.

Better Buy: DexCom vs. Abbott Laboratories

Dexcom Can Exceed Market's Expectations Again In 2020, And Beyond

Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

Livongo Health Inc

Data from DexCom's continuous glucose monitoring system will be available to users of Livongo's software platform.

DexCom and Livongo Health Team up in Glucose Data Deal

Dexcom CGM to become a core part of Livongo’s solution for delivering personalized health insights and improved clinical outcomes to people with Diabetes Dexcom CGM to become a core part of Livongo’s solution for delivering personalized health insights and improved clinical outcomes to people with Diabetes

Livongo and Dexcom Partner to Integrate Dexcom’s G6 Continuous Glucose Monitoring System into Livongo’s Applied Health Signals Platform

Provention Bio Inc

It's a $45 billion market -- here are some winners that could keep winning.

News for DexCom Stock (DXCM)